On Thursday, Viking Therapeutics (NASDAQ:VKTX) received a favorable initiation of coverage from Jefferies, with a Buy rating and a price target set at $110.00. The... Biotech firm Viking ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

The stock also underperformed the broader Medical sector and the S&P 500 during this timeframe, as shown in the chart below. VKTX’s shares are currently trading below the 50 and 200-day moving ...

The chart below shows the one year performance of VKTX shares: Looking at the chart above, VKTX's low point in its 52 week range is $20.28 per share, with $99.41 as the 52 week high point — that ...

Investing.com - Viking Therapeutics Inc (NASDAQ: VKTX) reported first quarter EPS of $-0.250, $0.01 worse than the analyst estimate of $-0.240. Revenue for the quarter came in at ...

The stock also underperformed the broader Medical sector and the S&P 500 during this timeframe, as shown in the chart below. VKTX’s shares are currently trading below the 50 and 200-day moving ...